Recent studies have suggested that dierent mutation types within the core domain of the tumour suppressor protein p53, i.e. DNA contact mutations and structural mutations, confer dierent biological properties. We have analysed in 86 head and neck squamous cell carcinomas (HNSCC), whether these p53 mutation types have a dierential clinical impact. Thirty-seven missense mutations were identi®ed. Thirteen of these (36%) were DNA contact mutations, occurring in the L3 loop, in the H2 loop sheet helix motif, in the S10 b strand and in Zinc binding residues. Microsatellite marker analysis revealed a selective association between these mutations and the loss of wild-type alleles (100% LOH vs 50% LOH in tumours with structural mutations; P=0.0034, Fisher's exact, 2-tailed). In comparison to structural mutations or to the absence of mutations in the core domain, DNA contact mutations were associated with higher tumour stages (84.6% vs 62%), a higher incidence of lymph node metastasis (91.7% vs 56%; P=0.014, Fisher's exact, 2-tailed), a shortened recurrence-free survival (8.1 months vs 23.7 months, P=0.047, log rank test) and overall survival (11 months vs 29.2 months; P=0.003, log rank test). The latter was also the case when only stage IV tumours were analysed (P=0.0055, log rank test). These data indicate that in HNSCC, TP53 DNA contact mutations confer a strong selection pressure to eliminate wild-type alleles, and that they result in an accelerated tumour progression and reduced therapeutic responsiveness.
Introduction
The great majority of tumours arising in the head and neck region are squamous cell carcinomas (HNSCC). Alterations in the p53 tumour suppressor protein which, in its wild-type form, plays crucial roles in cell cycle checkpoint control and in the regulation of apoptosis (Ko and Prives, 1996; Levine, 1997 ) is a common feature in HNSCC. However, no correlation between p53 mutations and clinical parameters has been found (Boyle et al., 1993; Ahomadegbe et al., 1995) . In contrast, for some cancer types evidence has been obtained that p53 mutations are associated with worsened clinical outcome, e.g. in breast cancer (Andersen et al., 1993) and in colorectal cancer (Hamelin et al., 1994) . Furthermore, some speci®c types of mutations located in regions involved in DNA binding have been shown to correlate with resistance to primary and adjuvant therapy and with survival in breast cancer (Bergh et al., 1995; Aas et al., 1996) and colorectal cancer (Goh et al., 1995) . Whether speci®c mutation types have a dierential eect in HNSCC, has thus far not been examined.
The crystal structure of the p53 protein core domain bound to consensus DNA which was recently elucidated (Cho et al., 1994) , has greatly increased our understanding of the spatial location of important amino acids or peptide domains and the impact of the corresponding mutations on either protein structure/ stabilization or interaction with DNA. Particularly, this study has demonstrated that dierent mutations within the core domain which is roughly equivalent to the exons 5 ± 8 of the gene, will have highly divergent eects on the structure, stability and sequence speci®c DNA binding properties of the protein. The hot spot mutations most frequently observed in human tumours are located in two of three regions directly interacting with DNA, the helix ± loop ± helix motif H2 and the L3 loop containing the arginine residue of codon 248. The coordinated binding to a zinc atom of four amino acid residues, Cys-176 and His-179 (L2 loop), Cys-238 and Cys-242 (L3 loop) has also been implicated in promoting DNA binding.
The proposals coming forward from this study have been largely con®rmed, but with some important limitations. All DNA contact mutations examined were found to inhibit or completely block sequence speci®c DNA binding, but to have only limited and locally restricted consequences on the stability and conformation of the whole p53 protein. Most notable, for some of these mutant proteins it was shown that co-translation of wild-type p53 in vitro resulted in hetero-oligomerization and partial restoration of mutant DNA binding (Rolley et al., 1995) . Interestingly, the eects of DNA contact mutations on wildtype p53 transactivation function were found to be cell type dependent in vivo (Forrester et al., 1995) . It was further shown by analysing DNA contact mutants in p53 null cells that the transactivating domain at the NH2 terminus remained functionally intact (Dittmer et al., 1993; Hsiao et al., 1994) , consistent with a`gain of function' character of these mutations as had been previously proposed (Michalovitz et al., 1991) . On the other hand, while some mutations located in the bulk of the b sandwich appeared to completely denature the protein as proposed (Cho et al., 1994) , thus destroying DNA binding as well as transactivating activity (Dittmer et al., 1993) , a number of mutations actually partly retained DNA binding function in vitro (Rolley et al., 1995) .
In the context of the possible impact of dierent p53 mutation types on the biological and clinical tumour behaviour, the allelic status of the p53 gene (number of mutant alleles vs number of wild-type alleles) has to be considered as well. It is generally assumed, but not necessarily the case, that any mutation in p53 (or any other tumour suppressor gene) will result in the loss of the remaining wild-type allele. Indeed, no association was found in HNSCC between loss of heterozygosity (LOH) for the TP53 locus and mutation (Ahomadegbe et al., 1995) . Interestingly, in a study on Li-Fraumeini tumour patients, LOH for the wild-type allele was observed in less than half of cases carrying p53 germ line mutations, and there was some evidence for LOH being associated with mutation types (Varley et al., 1997) .
These considerations have therefore prompted us to investigate whether certain speci®c mutation types, and possibly the allelic status of the p53 gene, might add signi®cant information as to the malignant potential of individual tumours and might be of prognostic and predictive value in HNSCC. On the basis of the study of Cho and coauthors (Cho et al., 1994) , we have tested the hypothesis that mutations directly interfering with DNA binding might constitute`gain of function' mutations with a stronger impact on tumour progression, therapeutic response and patient prognosis, whereas mutations distal from the DNA binding surface might constitute loss of function mutations with less severe biological and clinical impact. We have also tested whether there is a dierential selection pressure towards loss of the wild-type p53 allele associated with these putative mutation types. Our results indicate that the speci®c mutation present in an individual tumour is relevant for both the elimination of wild-type alleles and the clinical course of the disease.
Results

p53 mutational analysis in HNSCC
From a larger cohort of HNSCC, 86 previously untreated primary tumours were selected for studying the mutational and allelic status of the p53 gene. Selection criteria was representative participation of the dierent tumour locations and tumour stages (Table 1) . Mutations were analysed in exons 5 ± 8 which contain the coding sequence for the central portion of the protein. Mutations therein either directly aect sequence speci®c DNA binding or disturb to a varying extent the conformation of the p53 protein. Table 2 presents all cases analysed, starting o with the 40 cases in which sequence changes were identi®ed and the clinical tumour data. Three of these changes were silent mutations/polymorphisms occurring at codons 158 (silent mutation) and 213 (polymorphism, two cases). One frameshift mutation, a 1 bp insertion in codon 150, and one in-frame deletion was detected. The mutated protein encoded by the in-frame deletion gave a strong immunohistochemical nuclear staining (not shown). Thirty-®ve missense mutations resulted exclusively in amino acid substitutions. Ten of these were located in exon 5, seven in exon 6, ten in exon 7, eight in exon 8. The missense mutations included 19 transitions (G : C?A : T in 10 cases and A : T?G : C in nine cases) and 16 transversions (A : T?C : G in three cases, A : T?T : A in two cases, T : A?A : T in one case, C : G?A : T in one case, G : C?T : A in four cases, G : C?C : G in one case, T : A?G : C in one case, and C : G?G : C in three cases). Examples of electropherograms identifying DNA contact and structural mutations are presented in Figure 1a and b, respectively.
Spectrum of p53 gene mutations
Spectrum of DNA contact p53 mutations
As indicated in Table 2 , 13 mutations occurred within the structural domains which are critical for DNA binding, i.e. the L3 loop, the H2 helix, the S10 b sheet and Zn binding residues. Four of these were located in the S10 domain and two in the H2 domain which interacts with the major groove of the DNA double helix. Of the four mutations in the L3 loop, two were located at codon 248, coding for the arginine residue which directly binds DNA, and one at codon 242 which encodes a cysteine. This cysteine residue as well as cysteine at codon 176 (loop 2, found in one tumour) is critical for the three dimensional structure of the DNA binding surface brought about by binding and complexation of a zinc atome (Cho et al., 1994) . The deletion already mentioned encompassed codons 273 ± 283 and therefore aected part of S10 as well as most of the H2 domain which directly interacts with the major groove of the DNA. In our tumour cohort, we have thus far not detected mutations in the L1 loop which is also involved in DNA interaction, neither have we found mutations of Arg at codon 175 which is one of the major hot spots for mutations when all human cancers are considered.
Allelic loss of p53 is speci®cally correlated with DNA contact mutations
The results described so far raised the question of whether every type of p53 mutation in our tumour cohort resulted in the loss of the remaining wild-type allele(s). It seemed possible that the loss of heterozygosity might be preferentially associated with speci®c mutations, i.e. the mutations critical for direct DNA binding. Therefore, in 51 tumours the allelic status of p53 was analysed by microsatellite analysis using the TP53 marker (Jones and Nakamura, 1992), of which only one case was not informative. Examples are presented in Figure 1c ± e. In most cases, LOH as assessed by microsatellite marker analysis was con®rmed by the complete absence of the wild-type band in the electropherogram in the sequence analysis (compare Figure 1a with c, and Figure 1b with d) . Table 3 presents a summary of the results of these analyses and the statistical evaluation. The results show that LOH of the TP53 locus at 17p13 per se is not signi®cantly correlated with clinical parameters such as tumour stage or lymph node involvement. However, LOH of p53 is selectively associated with mutations in the L3, H2, S10 domains and in Zn binding residues. All tumours analysed with mutations in these domains showed LOH, whereas only 10 of 22 cases with mutations outside of these domains showed LOH.
LOH analysis interpretation can be compromised by extensive chromosomal imbalances (unpublished observations). Since trisomy and polysomy of chromosome 17 was frequently noted in HNSCC (Soder et al., 1995, and unpublished results) , dual-color FISH with a Figure 1 Examples of TP53 mutation types and results of microsatellite marker analyses at the TP53 locus. The electropherograms show a DNA contact mutation at codon 273 (a, case 2/4/56 in Table 2 ), and a structural mutation at codon 158 (b, case 3/1/42 in Table 2 ). Cycle sequencing was performed on microdissected tumour DNA from frozen sections. WT, wild-type sequence; MUT, mutated sequence; see arrow heads. Note that in b the wild-type band is also present in the sequence. The microsatellite elecropherograms show allelic loss (LOH) in a tumour (T; N, denotes corresponding normal tissues) with a DNA contact mutation (c; same case as in a), no allelic loss in a tumour with a structural mutation (d; same case as in b), and LOH in a tumour with a structural mutation (e; case 3/2/43 in Table 2 ). Arrow heads point to the two alleles. For further details, see Materials and methods TP53 DNA contact mutations in head and neck cancer R Erber et al centromeric chromosome 17 probe and a p53 locusspeci®c cosmid cocktail probe was performed on some ambiguous cases. Figure 2 shows an example of such an analysis of a tumour disomic for chromosome 17 but with only one copy of the TP53-locus.
Comparison of p53 mutations with the clinical course of the disease
In order to examine whether p53 mutations had any impact on disease progression, the clinical data of the tumours expressing a mutated p53 protein were compared with those not revealing a mutation. In contrast to p53 protein accumulation (Nees et al., 1993; and unpublished results) , the presence of mutations tended to occur in higher tumour stages (Table 4) . Accordingly, there was also a tendency towards shorter recurrence-free (not shown) and overall survival times of tumour patients with p53 mutation (Figure 3a ), but the dierence to tumour patients without p53 mutations in exons 5 ± 8 did not reach signi®cance. It was next asked whether speci®c mutation types had a dierential in¯uence on tumour progression. This analysis revealed a very strong association of the group of DNA contact mutations with the clinical course of the disease (Table 4) .
Tumours with DNA contact mutations are associated with worsened patient prognosis
As can be seen from Table 4 , 12 of the 13 patients with DNA contact p53 mutations (92%) presented with lymph node metastases at ®rst diagnosis, in contrast to 41 of 73 patients with structural mutations or without Fisher's exact Fisher's exact LOH was only recorded when a reduction in the ratio of allele signal intensities of q=0.5 occurred in the tumour sample relative to that in the corresponding normal sample. N0, N+, negative/positive for lymph node metastasis Figure 2 Dual-Colour-FISH with centromeric chromosome 17 probe (green) and TP53 locus speci®c cosmid probe (red) on isolated tumour cell nuclei containing a DNA contact mutation (codons 273 ± 284, 36 bp deletion, case 1/5/26 in Table 2 ). The tumour cells contain two copies of the chromosome 17 centromer (green signals), but only one copy (the mutated allele) of the TP53 locus (red signal) As can be seen from the Kaplan ± Meier curves in Figure 3b , the patients with tumours harbouring structural mutations and the patients without mutations in exons 5 ± 8 had similar survival rates, in contrast to the patients with DNA contact p53 mutations (Figure 3b) . Therefore, the former two groups were combined and compared with the group of patients with DNA contact mutations, using the log rank test. Figure 3c and d demonstrate the impact of DNA contact mutations on the recurrence-free survival times and on the overall survival times. The DNA contact p53 mutations described were strongly associated with a shortened recurrence-free survival (8.1 months vs 23.7 months, P=0.047; Figure 3c ) and also with a shortened overall survival (11.0 months vs 33.9 months, P=0.003; Figure 3d ). Finally, we examined whether the association of DNA contact mutations with a worsened clinical outcome was independent of the tumour stage, by analysing stage IV tumours only. As shown in Figure 3d , the overall survival times of patients whose tumours carried p53 DNA contact mutations were still signi®cantly shorter than of the other stage IV tumour patients (10.5 months vs 23.8 months, P=0.0055), despite a lowered number of cases in both groups.
Sixty-eight of the 86 patients included in this study received complete postoperative radiation therapy, including all cases with DNA contact mutations and nearly all stage IV tumour patients. Therefore, the observed association between DNA contact mutations and worsened clinical outcome is also a close re¯ection of a lesser treatment responsiveness of residual tumour cells with DNA contact mutations.
Discussion
In this study evidence is provided that speci®c mutations in the TP53 gene aecting the structural domains L3, H2, S10 and the Zn binding amino acids within the core domain of the p53 protein have a strong and dierential impact on the biological and clinical behaviour of HNSCC. The impact of these mutations which result in impaired or loss of sequence speci®c DNA binding but have only limited consequences on the overall structural integrity of the p53 protein (Cho et al., 1994) , appears to be twofold: (i) it has been suggested for several of these mutations that they have`gain of function' characteristics, thereby conferring a selective growth advantage upon transfected cells in culture and/or in experimental animal models (Dittmer et al., 1993; Hsiao et al., 1994; Lin et al., 1995;  (ii) they confer an increased resistance against anti-tumour therapies and drugs (Bergh et al., 1995; Aas et al., 1996) . The clinical impact of the corresponding mutations described here, i.e. their signi®cant association with high tumour stages, is consistent with such oncogenic`gain of function' properties. As described here for the ®rst time for squamous cell carcinomas, in HNSCC harbouring such mutations there is a much stronger selection pressure to eliminate remaining wild-type allele(s) than in Whereas the Kaplan ± Meier curves of patients with structural mutations and patients without TP53 mutations were similar, those of patients with DNA contact mutations were distinctly dierent as revealed by the log rank test. (c, d) Comparison of recurrence-free (RFS, c) and overall survival (d) between patients with DNA contact mutations and patients with structural mutations and without TP53 mutations. DNA contact mutations were associated with shortened survival times (P=0.047 for recurrence-free survival; P=0.003 for overall survival, log rank test. (e) After strati®cation for tumour stages, the overall survival of patients with DNA contact mutations remained signi®cantly shorter as compared with those with structural mutations and without mutations (P=0.0055; log rank test). The survival percentages are on the y-axis, the follow up times in months on the x-axis. Number of cases included for Kaplan ± Meier survival analysis are displayed for each diagram. Censored patients are denoted in Table 2 TP53 DNA contact mutations in head and neck cancer R Erber et al tumours harbouring mutations in the bulk of the b sandwich of the core domain. For the latter types of mutations which generally lead to an extended denaturation of the p53 protein, it was shown that they are unable to impose a new phenotype, consistent with a loss of function character (Dittmer et al., 1993; Lin et al., 1995) . Together, the acquisition of a`gain of function' mutation and the selective loss of p53 wildtype alleles appears to deliver highly malignant growth properties as well as resistance against radiation therapy. Thus, as demonstrated in Figure 3 , DNA contact mutations are strongly indicated as tumour stage-independent prognostic markers in HNSCC.
The dierential association between mutation type with allelic loss as well as with clinical parameters in HNSCC may be based on a dierential interaction between either DNA contact or structural mutant protein and the wild-type p53 protein in dierent cell types. The restoration of sequence speci®c DNA binding and transactivation of DNA contact mutants in vitro by co-translated wild-type protein (Rolley et al., 1995) strongly suggests a pronounced selection pressure to eliminate the wild-type allele(s). In contrast, a reduced or absent selection pressure to eliminate the wild-type allele(s) can be expected in the case of those structural mutants which have partially or fully retained DNA binding capacity. Importantly, as was recently shown, the impact of the type of mutation (DNA contact or structural) in vivo is also in¯uenced by the cell type, both regarding the transactivation function of p53 in vivo (Forrester et al., 1995) as was regarding the tumorigenic phenotype (Dittmer et al., 1993) . It is therefore conceivable that the selection pressure exerted by dierent mutation types to eliminate the wild-type allele(s) is also cell type dependent. Indeed, Varley and colleagues (Varley et al., 1997) have reported evidence of a cell type speci®c association between the p53 mutation type in dierent tumour entities from Li ± Fraumeini patients. Whereas in breast tumours DNA contact mutations in codon 248 were accompanied by LOH, in tumours derived from non-epithelial cell types with the same mutations no LOH was observed.
In good agreement with previous reports (Boyle et al., 1993; Ahomadegbe et al., 1995) , the sequence changes found in the majority of cases were transitions (51.3%, again the majority being G : C?A : T) rather than transversions as might have been expected from the very strong prevalence of tobacco consumption among the patients. Furthermore, the percentage of hot spot mutations at the DNA binding surface of the p53 protein core was lower than that reported for all tumour types (Greenblatt et al., 1994) . It might be worth mentioning that we found three G : C?A : T transitions at codon 266 in the S10 domain (8.1% in our cohort vs 0.2% in all HNSCC and 0.9% in all tumour types; Hollstein et al., 1996) .
In the previous reports mentioned above in which sizeable HNSCC cohorts have been screened for p53 mutations (Boyle et al., 1993; Ahomadegbe et al., 1995) , the presence of (any) mutation did not emerge as prognostic factor, neither was the selective association with DNA contact mutation types with LOH of TP53 examined for. Although we cannot rule out the possibility that a small percentage of the`wild-type' tumours in our study actually contained mutations outside of exons 5 ± 8 (Brachman et al., 1992 ; for review, see Greenblatt et al., 1994) , our results were largely in agreement in that the presence of any p53 mutation is not a signi®cant prognostic indicator in HNSCC, in contrast to other tumour entities such as colon cancer and breast cancer. In two large studies on sporadic breast cancer, a similar selective association between DNA contact mutations and poor prognosis has been found as in our study, although LOH analysis was not performed (Bergh et al., 1995; Adas et al., 1996) . It remains to be investigated whether this association holds true for all epithelial cancers with a substantial involvement of p53 mutations. It will also be interesting to examine, e.g. by dierential display methodology, whether DNA contact mutations in HNSCC together with LOH of the TP53 locus are also associated with the aberrant transcriptional activation of cellular genes which contribute to tumour progression and are not activated by wildtype p53, e.g. MDR1 (Dittmer et al., 1993) , VEGF (Kieser et al., 1994) or inhibitors of apoptosis such as bcl-2 (Miyashita et al., 1994) . This would add further support for`gain of function' characteristics of such mutations. Conversely, it will be interesting to examine whether DNA contact mutations in squamous epithelial cells lose the capacity to transactivate apoptosis promoting genes such as bax (Ory et al., 1994; Friedlander et al., 1996) .
In conclusion, we have described a signi®cant impact of DNA contact p53 mutation types on the biological and clinical behaviour of HNSCC, including the poor responsiveness of such mutations toward adjuvant radiation therapy. At present, no proposals can be made as to therapeutic consequences of our data. Rather, squamous cell carcinoma derived cell lines with speci®c p53 mutation types and de®ned p53 allelic status should be extensively examined with regard to their responsiveness towards established and newly developed chemotherapeutical as well as gene therapeutical compounds. This might then form the basis for a more individual therapy in the future.
Materials and methods
Patients and biopsy material
Eighty-six previously untreated patients were included in this study, 73 males and 13 females. The median age was 54 years, ranging from 32 to 89 years. Most of the patients had a history of heavy smoking and drinking. The tumour sites and clinical characteristics are presented in Table 1 . The tumours were grouped according to the TNM classi®cation (UICC, 1987) and staged as recommended by the American Joint Committee on Cancer (AJCC). Tumour biopsies were obtained with the patients consent at the Ear, Nose and Throat University Hospital, Heidelberg, and were divided into two parts. One part was snap-frozen in liquid nitrogen immediately after surgery and stored at 7808C, a second part was formalin-®xed and paran-embedded. Histopathological assessment on paran sections was kindly performed by Dr AI Born, Institute of Pathology, University of Heidelberg.
PCR-cycle sequencing of p53 exons 5 ± 8
Tumour-DNA was prepared from microdissected tissues using the Qiamp tissue kit from Qiagen (Hilden, Germany). PCR was performed using nested primers after initial TP53 DNA contact mutations in head and neck cancer R Erber et al ampli®cation of a PCR-fragment containing exons 5 ± 8. Primers were designated 2996, 2999 for exons 5 ± 8, 3878, 2997 and 2998, 5252 for exons 5 ± 6 and exons 7 ± 8, respectively. PCR was performed in an reaction volume of 50 ml, in 16PCR-Buer (Promega, Madison, WI) with 3.0 mM MgCl 2 (2996, 2999); 2.0 mM MgCl 2 (2997, 3878) and 1.5 mM MgCl 2 (2998, 5252), with 15 pmol of each primer, 200 mM of each dNTP and 1.5 U Taq-DNAPolymerase (Promega, Madison, WI). Cycling conditions were 948C/3 min (initial denaturation), 948C/30 s, 608C/ 40 s, 728C/20 ± 60 s (30 cycles) and 728C/3 min on a Hybaid Omnigene Thermal Cycler (MWG-Biotech, Ebersberg, Germany). PCR products were puri®ed using the PCR puri®cation kit by Qiagen (Hilden, Germany), and sequenced using a DyeDeoxy Terminator Cycle sequencing Kit (ABI-Perkin Elmer, Weiterstadt, Germany) on an ABIPrism 310 Genetic Analyser (ABI-Perkin Elmer, Weiterstadt, Germany). Exons 5 ± 8 were completely sequenced in all cases, mutations were con®rmed by sequencing the opposite strand. Primers used for PCR: 2996, 5'-TATCTGTTCACTTGTGCCCTG-3'; 2997, 5'-CCACT-GACAACCACCCTTAAC-3'; 2998, 5'-TCATCTTGGGC-CTGTGTTATC-3'; 2999, 5'-GAATCTGAGGCATAACT-GCAC-3'; 3878, 5'-TTCCTCTTCC-TACAGTACTCC-3'; 5252, 5'-TCTTGTCCTGCTTGCTTACCT-3'.
Microsatellite marker analysis: allelic loss at TP53 locus
The LOH analysis for the p53-locus was performed by PCR-ampli®cation of microsatellite repeat sequences using the published sequences as primers (Jones and Nakamura, 1992). The upstream primer was HEX-labelled. Each PCRreaction contained 10 ± 100 ng of DNA, 5 pmol of each of the primers, 2.5 nmol of each of the four deoxyribonucleotide triphosphates (Boehringer, Mannheim, Germany), 0.6 U of Taq DNA-Polymerase (Promega, Madison, WI) in 15 ml PCR-buer with 1.5 mM MgCl 2 . Samples were ampli®ed by ®ve initial cycles of denaturation for 15 s at 948C, annealing for 15 s at 558C, and extending for 30 s at 728C, and for additional 20 cycles of denaturation at 898C, annealing for 15 s at 558C, and extending for 30 s at 728C. After ampli®cation, PCR samples were diluted 1 : 15 in formamide, heated to 958C for 2 min, chilled on ice and analysed on an ABI PRISM 310 (ABI-Perkin Elmer, Weiterstadt, Germany) with the GeneScan Software. LOH was inferred when a reduction in the ratio of allele signal intensities of q=0.5 occurred in the tumour sample relative to that in the corresponding normal sample.
Fluorescence in situ hybridization (FISH) with centromeric and p53 locus speci®c cosmid probes
The FISH analyses were performed on tumour cell suspensions (cytospins). The DNA probe speci®c for the centromer of chromosome 17 was labelled with biotin by nick translation. Locus speci®c probes, directly fluorochrome-labelled were obtained from Vysis (Stuttgart, Germany). For dual hybridization, denaturation of the probe cocktail and of the single cell suspensions was performed separately. Avidin-FITC was used for detection of biotin labelled probes. The procedure was performed essentially as described previously (Soder et al., 1995) .
Statistical analysis
The Fisher's exact test was used for univariate analyses. The initial signi®cance level of a=0.05 was adjusted for multiple testing (n=2) by means of the Bonferroni procedure. The resulting signi®cance level relevant for this study was a=0.025. The Kaplan ± Meier method was used to generate survival curves and these were evaluated using the log rank test. Both recurrence-free as well as overall survival times were calculated from the date of surgery.
